Document AbbVie Inc. Guidance Including the Impact of Acquired IPR D and Milestones Expense (Unaudited) (in millions, except per share data) Quarter Ended
Monday, March 31, 2025 1 min read
Key Takeaway: AbbVie Inc. has provided updated guidance for Adjusted Diluted EPS, accounting for an acquired IPR D and milestones expense. The guidance reflects a minor decrease in EPS for Q1 2025 due to these expenses, with a proposed range of $2.34 to $2.38. For the full year of 2025, AbbVie projects an Adjusted EPS range of $11.99 to $12.19. Additionally, any impacts from future expenses beyond the first quarter remain unpredictable, highlighting some uncertainty.
Market Sentiment Analysis
POSITIVE FACTORS
AbbVie's guidance for Adjusted Diluted EPS remains strong despite expenses.
The Q1 2025 guidance reflects a minor impact from acquired IPR D.
Full-year Adjusted EPS guidance includes a range indicating stability.
CONCERNS & RISKS
Expenses from acquired IPR D and milestones are expected to affect Q1 2025 earnings.
The guidance does not account for any unforeseen expenses beyond Q1 2025.
Full Press Release Details
Guidance Including the Impact of Acquired IPR D and Milestones Expense
(in millions, except per share data)
Quarter Ended March 31, 2025
Full-Year Ended December 31, 2025
Acquired IPR D and Milestones Expense
Adjusted Diluted EPS Range
Acquired IPR D and Milestones Expense
Adjusted Diluted EPS Range
Low
High
Low
High
Previously announced guidance excluding Q1 2025 acquired IPR D and milestones expense
$
-
$
2.47
$
2.51
$
-
$
12.12
$
12.32
Q1 2025 acquired IPR D and milestones expense
248
(0.13)
(0.13)
248
(0.13)
(0.13)
Guidance including Q1 2025 acquired IPR D and milestones expense a
$
248
$
2.34
$
2.38
$
248
$
11.99
$
12.19
a The Company's 2025 adjusted diluted EPS guidance excludes any impact from acquired IPR D and milestones expense that may be incurred beyond the first quarter of 2025, as both cannot be reliably forecasted. This guidance does not reflect the impact related to AbbVie and Gubra's licensing agreement to develop GUB014295, as that transaction closed after the first quarter of 2025.
Frequently Asked Questions
What is the Q1 2025 acquired IPR D expense?
The Q1 2025 acquired IPR D expense is $248 million.
What is the adjusted diluted EPS range for 2025?
The adjusted diluted EPS range for 2025 is between $11.99 and $12.19.
How does the Q1 2025 expense affect EPS guidance?
Including the Q1 2025 expense, the adjusted diluted EPS guidance ranges from $2.34 to $2.38.
Are future expenses from IPR D included in the guidance?
Future IPR D and milestone expenses beyond Q1 2025 are not included in the guidance.
What was the previous EPS guidance excluding Q1 2025 expenses?
The previous EPS guidance was between $2.47 and $2.51.